Mechanisms of adverse effects of anti-VEGF therapy for cancer
By T. Kamba, D. McDonald. British Journal of Cancer, 2007
992 citations recorded by the source corpus.
Advances in understanding the role of vascular endothelial growth factor (VEGF) in normal physiology are giving insight into the basis of adverse effects attributed to the use of VEGF inhibitors in clinical oncology. These effects are typically downstream consequences of suppression of cellular signalling pathways important in the regulation and maintenance of the microvasculature. Downregulation of these pathways in normal organs can lead to vascular disturbances and even regression of blood vessels, which could be intensified by concurrent pathological conditions. These changes are generally manageable and pose less risk than the tumours being treated, but they highlight the properties shared by tumour vessels and the vasculature of normal organs.
Subfields: Cancer Research, Cardiology and Cardiovascular Medicine, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/ac1c0ec2935eabd3ac09a6f4a960847ec896ab33
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
Citations in the corpus
- Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management (2016, background): “duction in the wall of arterioles, increased endothelin-1 production, and capillary rarefaction that results in the reduction of effective capillary beds.(12,77) In addition, VSP inhibitor-induced hypertension is perhaps related to”
- Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. (2012, background): “However, several theories have been proposed, including an imbalance in neurohumoral factors, the development of vascular rarefaction or an alteration in vascular nitric oxide balance [38, 39].”